Results 51 to 60 of about 9,592 (241)

Efficacy of Sovodak in the Management of Patients Co-infected with HIV/HCV [PDF]

Advanced Pharmaceutical Bulletin, 2020
Purpose: Sofosbuvir (SOF) and daclatasvir (DOC) are suggested for the treatment of hepatitis C virus (HCV) in patients with concomitant HCV and human immunodeficiency virus (HIV). In 2016, Sovodak tablet a combination of SOF and DOC was introduced.
Mohammad Hossein Somi, Bita Sepehri, Zeinab Nikniaz, Roya Sedghi   +3 more
doaj   +1 more source

Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C [PDF]

, 2013
Recurrent HCV infection following liver transplantation can lead to accelerated allograft injury that is difficult to treat with interferon. The aim of this study is to describe the first ever use of an interferon‐free, all oral regimen in a liver ...
Appelman, H., Bifano, M., Dimitrova, D., Fontana, R. J., Hindes, R., Hughes, E. A., Symonds, W. T.   +6 more
core   +1 more source

Update on hepatitis C virus resistance to direct-acting antiviral agents [PDF]

, 2014
Review[Abstract] Resistance to direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) infection is driven by the selection of mutations at different positions in the NS3 protease, NS5B polymerase and NS5A proteins.
Cachay, Edward, Castro-Iglesias, Ángeles, Mena, Álvaro, Pedreira, José D., Poveda, Eva, Wyles, David L.   +5 more
core   +2 more sources

Resolved HBV Infection Is Not Associated With Liver‐Related Outcomes in Survival Analysis of Caucasians After HCV Cure

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background Previous exposure to hepatitis B virus (HBV) may influence the risk of developing hepatocellular carcinoma (HCC) and other liver‐related events (LRE), in particular in patients after HCV cure. Previous studies were not conclusive and there are only few large studies on this topic from Europe. Methods We analysed clinical endpoints (≥
Laura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, Christine John, Ralph Link, Hartwig Klinker, Uta Merle, Markus Cornberg, Christoph Sarrazin, Thomas Berg, Heiner Wedemeyer   +10 more
wiley   +1 more source

Evaluation of Patients' Recovery from Hepatitis C Following Antiviral Treatment with Daclatasvir and Sofosbuvir in AL-Baha Region [PDF]

International Journal of Advanced Humanities Research
The liver is the largest organ in the body, located below the diaphragm and protected by the lower ribs of the rib cage (Johns Hopkins Medicine, 2022).
Fahad Alghamdi, Rashed Mohammed
doaj   +1 more source

Current trends in the treatment of hepatitis C [PDF]

, 2016
Viral hepatitis, an inflammatory liver disease, is caused by various genotypes of hepatitis C viruses (HCV). Hepatitis C slowly sprouts into fibrosis, which progresses to cirrhosis.
Akhtar, Bushra, Akhtar, Muhammad Furqan, Muhammad, Syed Taqi, Mushtaq, Muhammed Fahd, Peerzada, Sohaib, Saleem, Ammara, Saleem, Muhammad, Sharif, Ali   +7 more
core   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source

DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR

International Journal of Pharmacy & Integrated Health Sciences
Background: Sofosbuvir (SOF) and daclatasvir (DCV) are usually prescribed in combination for the treatment of hepatitis C worldwide. Objectives: In the present study a novel, simple, rapid, and cost-effective reversed-phase high performance liquid ...
Syed Hassan Murtaza, Ahmed Umer Sohaib Ahmed, Tassawer-e-Meran, Sonam Anees, Najam-ul-Hassan Khan, Kishwar Sultana   +5 more
doaj   +1 more source

Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort [PDF]

, 2016
[Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical
Alonso, S., Ampuero, J., Badia, E., Baliellas, C., Buti, M., Carrión, J.A., Castro-Iglesias, Ángeles, Devesa, M.J., Esteban, R., Fernández, I., Fernández-Carrillo, C., Fernández-Rodríguez, C.M., Gea, F., Granados, R., Gómez, A., Lens, S., Llerena, S., Montero, J.L., Olveira, A., Pascasio, J.M., Planas, J.M.M., Polo, B., Real, Y., Rincón, D., Riveiro-Barciela, M., Rubín, A., Salmerón, J., Turnes, J.   +27 more
core   +2 more sources

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, Volume 56, Issue 5, Page 778-783, May 2026.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source